Onametostat
- Generic Name
- Onametostat
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Phase 1
- Conditions
- Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-HodgkinMyelodysplastic SyndromesNeoplasmsSolid Tumor, AdultMetastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2025-01-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06788509
- Locations
- 🇨🇳
Chang Kung Memorial Hospital, Kaohsiung City, Taiwan
🇧🇪Ghent University Hospital, Gent, Belgium
🇫🇷Hopital Claude Huriez, Lille, France
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
Phase 1
Active, not recruiting
- Conditions
- Solid Tumor, AdultNeoplasmsMyelodysplastic SyndromesNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 114
- Registration Number
- NCT03573310
- Locations
- 🇨🇦
Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada
🇺🇸Florida Specialist and Cancer Institute, Sarasota, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath